Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...

According to a ... Researchers Identify Protein Connected to Aging and Idiopathic Pulmonary Fibrosis July 25, 2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...